ArticleTargeted oncology2023

A Phase I, First-in-Human Study of PRL3-zumab in Advanced, Refractory Solid Tumors and Hematological Malignancies.

Cheng E Chee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.